Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo aims to keep advanced lung cancer in check longer

NCT ID NCT06497530

Recruiting now Disease control Sponsor: Guangzhou Institute of Respiratory Disease Source: ClinicalTrials.gov ↗

First seen Jun 10, 2026 · Last updated Jun 10, 2026

Summary

This study tests whether a combination of two drugs (lurbinectedin and serplulimab) can help keep extensive-stage small cell lung cancer from growing after initial treatment. About 30 adults whose cancer did not get worse after first-line chemo-immunotherapy will receive the combo as maintenance therapy. The goal is to see if it delays cancer progression and improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The first affiliated hospital of Guangzhou medical university

    RECRUITING

    Guangzhou, Guangdong, 51000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

EXTENSIVE-STAGE SMALL-CELL LUNG CANCER